As the importance of aurora kinases was recognized due to their significance in human biology and cancer therapy, the demand for aurora kinase inhibitors has been surmounting of late. Aurora kinases are a type of enzymes that play a significant role in cell proliferation. In the mitosis process, these enzymes undertake the responsibility of breaking down the genetic material of the parent cells via the control of chromatid segregation.
Based on type of aurora kinase enzymes, A, B, and C can be the key segments of the global market for aurora kinase inhibitors. While aurora A and B lead to tumerogenesis, aurora C is associated with spermatogenesis process. Although they are not associated with a certain type of cancer, some instances of cancer exhibit over-expression of a particular type of aurora kinases. Aurora B was found to be related to thyroid, breast, and colon, whereas aurora A was found to be associated with prostate, pancreatic, ovarian, cervical, lung, breast, and brain.
The report offers key information pertaining to the leading growth drivers, deterrents, and market trends. The key opportunities proffered by the different regional segments have been analyzed in detail, alongside relevant market data, charts, and figures. Efficient analytic tools such as the Porter’s Five Force analysis and SWOT analysis have been adopted by the study to produce accurate evaluations. The major players transacting in the global market for aurora kinase inhibitors are also assessed with regards to their market shares, product portfolios, and business strategies.
This report gives readers a comprehensive overview of the Aurora Kinase Inhibitors Market:
The rising incidence of cancer on a worldwide scale has been fuelling the demand for aurora kinase inhibitors recently. Cancer has been found to be one of the foremost factors increasing mortality rates over the globe. According to the World Health Organization (WHO), by the end of 2025 the number of cancer patients will reach nearly 19.3 million, which was 14.1 million during 2012. The study also reveals that more than 8.2 million people die from cancer, of which almost 522,000 are women diagnosed with breast cancer. While the mortality rates are higher in the developing regions of the world, the frequency of cancer is higher in developed countries.
The progress of the global market for aurora kinase inhibitors can receive a blow due to the exorbitant costs required in the development of these inhibitors. Small manufacturers might not possess enough capital to invest massively in the creation of advanced aurora kinase inhibitors. Moreover, lack of awareness among the developing economies can also restrict the expansion of the market. However, the adoption of several biological therapies in the domain of oncology will create opportunities for further expansion of the market.
Get accurate market forecast and analysis on the Aurora Kinase Inhibitors Market. Request a sample to stay abreast on the key trends impacting this market: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=4679
By geography, the global market for aurora kinase inhibitors can be segmented into Latin America, Middle East and Africa, Europe, Asia Pacific, and North America. The countries in North America witnessed greater growth when compared with other regions. As a result, North America accounted for the greatest portion of the global revenue. The continuous upgrading of the healthcare sector has been propelling the market for aurora kinase inhibitors in North America.
High growth rate of geriatric population and heightening incidence of cancer rates in Asia Pacific have been responsible for the burgeoning demand for aurora kinase inhibitors in the region. India, China, South Korea, Japan, Malaysia, and Indonesia are likely to contribute substantially to the growth of the market for aurora kinase inhibitors in Asia Pacific over the next few years.
Cyclacel Pharmaceuticals, Pfizer, Eli Lilly, GlaxoSmithKline, Millennium Pharmaceuticals, Merck, Bristol Myers Squibb, Celgene, Roche, Sanofi, and Novartis are some leading companies operating in the global market for aurora kinase inhibitors.
Transparency Market Research
90 State Street,
NY – 12207
USA – Canada Toll Free 866-552-3453